Equities

Torii Pharmaceutical Co Ltd

Torii Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)24.57
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jan 21 2022.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments44,00347,69242,210
Total Receivables, Net28,50222,86522,010
Total Inventory10,7428,9698,763
Prepaid expenses663307152
Other current assets, total4,23811,77024,157
Total current assets88,14891,60397,292
Property, plant & equipment, net2,0952,2822,078
Goodwill, net------
Intangibles, net429517512
Long term investments33,97030,28222,309
Note receivable - long term------
Other long term assets648646666
Total assets133,432133,689130,810
LIABILITIES
Accounts payable6,9816,5845,793
Accrued expenses931753812
Notes payable/short-term debt000
Current portion long-term debt/capital leases222283211
Other current liabilities, total4,3705,6015,556
Total current liabilities12,50413,22112,372
Total long term debt22241275
Total debt244524486
Deferred income tax------
Minority interest------
Other liabilities, total7721,0031,148
Total liabilities13,29814,46513,795
SHAREHOLDERS EQUITY
Common stock5,1905,1905,190
Additional paid-in capital6,4606,4536,445
Retained earnings (accumulated deficit)109,425108,846106,250
Treasury stock - common(1369)(1381)(1393)
Unrealized gain (loss)427117523
Other equity, total1.00(1)0
Total equity120,134119,224117,015
Total liabilities & shareholders' equity133,432133,689130,810
Total common shares outstanding282828
Treasury shares - common primary issue0.690.700.71
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.